{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:15:21Z","timestamp":1783574121751,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>To evaluate the effect of intravitreal faricimab injections on retinal venous diameter in proliferative diabetic retinopathy (PDR) patients with diabetic macular edema (DME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective cohort study included 46 PDR patients (46 eyes) with DME, treated between August 2024 and January 2025. All participants received intravitreal faricimab combined with panretinal photocoagulation (PRP). Best-corrected visual acuity (BCVA, logMAR), central foveal thickness (CFT, \u03bcm), microaneurysm (MA) count, hard exudates (HE), neovascularization (NV) area, and retinal venous diameter were assessed at baseline and at 1, 3, and 6 months post-treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant improvements in BCVA were observed at 1, 3, and 6 months (0.52 \u00b1 0.16, 0.48 \u00b1 0.18, 0.40 \u00b1 0.15 vs. baseline 0.66 \u00b1 0.18; all P &amp;lt; 0.05). CFT showed a significant reduction at all time points (381.35 \u00b1 40.75, 327.30 \u00b1 43.40, 297.56 \u00b1 35.81 \u03bcm vs. baseline 472.34 \u00b1 47.23 \u03bcm; all P &amp;lt; 0.05). The MA count showed no significant reduction at 1 month (P &amp;gt; 0.05) but decreased significantly thereafter (72.71 \u00b1 20.53 and 63.06 \u00b1 17.08 at 3 and 6 months, respectively; both P &amp;lt; 0.05). Reductions in HE area were not significant at 1 or 3 months (in 2 and 6 patients, respectively; both P &amp;gt; 0.05). At 6 months, a significant reduction in HE area was observed in 14 patients (P &amp;lt; 0.05). The NV area was significantly reduced at 1, 3, and 6 months compared to baseline (0.17 \u00b1 0.10 mm\u00b2, 0.17 \u00b1 0.09 mm\u00b2, and 0.17 \u00b1 0.08 mm\u00b2 vs. 0.98 \u00b1 0.17 mm\u00b2; all P&amp;lt;0.05). Retinal venous diameter showed no significant change at 1 and 3 months compared with baseline (both P &amp;gt; 0.05) but was significantly reduced at 6 months (299.40 \u00b1 19.56 \u03bcm; P &amp;lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intravitreal faricimab was safe and effective for PDR patients with DME. A trend toward morphological reversal of retinal venous diameter was demonstrated at 6 months, suggesting that faricimab may influence retinal microvascular remodeling through dual inhibition of the VEGF-A and Ang-2 pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1837934","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:21:31Z","timestamp":1783570891000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in retinal venous diameter in proliferative diabetic retinopathy patients with diabetic macular edema following faricimab treatment: an observational study"],"prefix":"10.3389","volume":"17","author":[{"given":"Hui","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Jinan Second People\u2019s Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jinan Huashi Ophthalmology Hospital","place":["Jinan, China"]},{"name":"Department of Ophthalmology, Qilu Hospital of Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Qilu Hospital of Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jinan Aier Eye Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jinan Aier Eye Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jinan Second People\u2019s Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Qilu Hospital of Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2018.0182","article-title":"Pathophysiology of diabetic retinopathy: the old and the new","volume":"42","author":"Kusuhara","year":"2018","journal-title":"Diabetes Metab J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31819a5fc2","article-title":"Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy","volume":"29","author":"Cho","year":"2009","journal-title":"Retina"},{"key":"B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000442026","article-title":"Ranibizumab for high-risk proliferative diabetic retinopathy: an exploratory randomized controlled trial","volume":"235","author":"Figueira","year":"2016","journal-title":"Ophthalmologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2156273","article-title":"Diabetic macular edema pathophysiology: vasogenic versus inflammatory","volume":"2016","author":"Romero-Aroca","year":"2016","journal-title":"J Diabetes Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00672-6","article-title":"Real-world outcomes of anti-VEGF therapy in diabetic macular oedema: barriers to treatment success and implications for low\/lower-middle-income countries","volume":"12","author":"Sam-Oyerinde","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119591","article-title":"Current treatments for diabetic macular edema","volume":"24","author":"Tatsumi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(99)90525-0","article-title":"Methods for evaluation of retinal microvascular abnormalities associated with hypertension\/sclerosis in the atherosclerosis risk in communities study11The authors have no proprietary interest in the equipment and techniques described in this article","volume":"106","author":"Hubbard","year":"1999","journal-title":"Ophthalmology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.27.3.143.16049","article-title":"Revised formulas for summarizing retinal vessel diameters","volume":"27","author":"Knudtson","year":"2003","journal-title":"Curr Eye Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.807687","article-title":"Effectiveness of panretinal photocoagulation plus intravitreal anti-VEGF treatment against PRP alone for diabetic retinopathy: a systematic review with meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100111","article-title":"YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale","volume":"2","author":"Eter","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0323088","article-title":"Short-term real-world outcomes of diabetic macular edema treated with intravitreal faricimab","volume":"20","author":"Hirakata","year":"2025","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1090964","article-title":"Retinal vein changes after treatment with aflibercept and PRP in high-risk proliferative diabetic retinopathy","volume":"10","author":"Zhao","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990022","article-title":"Pericyte loss in diabetic retinopathy: mechanisms and consequences","volume":"20","author":"Beltramo","year":"2013","journal-title":"Curr Med Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system","volume":"10","author":"Augustin","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-2130","article-title":"Correlation of flicker-induced and flow-mediated vasodilatation in patients with endothelial dysfunction and healthy volunteers","volume":"32","author":"Pemp","year":"2009","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.08.001","article-title":"The progress in understanding and treatment of diabetic retinopathy","volume":"51","author":"Stitt","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(13)38014-2","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41598-021-04593-x","article-title":"Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan","volume":"12","author":"Hsieh","year":"2022","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23509","article-title":"Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy: CLARITY substudy","volume":"59","author":"Nicholson","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-021-01773-6","article-title":"Retrospective study of aflibercept in combination therapy for high-risk proliferative diabetic retinopathy and diabetic maculopathy","volume":"41","author":"Tao","year":"2021","journal-title":"Int Ophthalmol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100160043006","article-title":"Subretinal fibrosis in diabetic macular edema. ETDRS report 23","volume":"115","author":"Fong","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.10.028","article-title":"Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials","volume":"122","author":"Domalpally","year":"2015","journal-title":"Ophthalmology"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1837934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:21:34Z","timestamp":1783570894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1837934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":25,"alternative-id":["10.3389\/fendo.2026.1837934"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1837934","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1837934"}}